Jupiter Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$78.6M Buy
126,099
+125,834
+47,485% +$85.7M 0.39% 72
2026
Q1
$205K Buy
+265
New +$203K ﹤0.01% 474
2024
Q4
Sell
-195
Closed -$205K 469
2024
Q3
$205K Buy
+195
New +$217K ﹤0.01% 394
2024
Q1
Sell
-372
Closed -$327K 512
2023
Q4
$327K Buy
+372
New +$306K ﹤0.01% 430
2023
Q3
Sell
-19,964
Closed -$14.3M 568
2023
Q2
$14.3M Sell
19,964
-6,654
-25% -$5.13M 0.16% 173
2023
Q1
$21.9M Buy
26,618
+2,625
+11% +$1.98M 0.3% 105
2022
Q4
$17.3M Buy
+23,993
New +$17.7M 0.25% 131
2022
Q3
Sell
-36,217
Closed -$21.4M 623
2022
Q2
$21.4M Buy
+36,217
New +$23.5M 0.3% 102
2021
Q1
Sell
-26,626
Closed -$12.8M 646
2020
Q4
$12.8M Buy
26,626
+11,645
+78% +$6.29M 0.13% 192
2020
Q3
$8.38M Buy
+14,981
New +$9.08M 0.09% 237

Other funds holding REGN

Jupiter Asset Management's REGN Position: Q2 2026 in Review

Jupiter Asset Management increased its Regeneron Pharmaceuticals (REGN) stake by 47,485% in Q2 2026, buying an estimated $85.7M and bringing the position to 126,099 shares worth $78.6M. The position accounts for 0.39% of the portfolio, ranked #72.

Jupiter Asset Management first reported a position in REGN in Q3 2020 and has held it in 10 quarters since. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Jupiter Asset Management held 126,099 shares of Regeneron Pharmaceuticals worth $78.6M as of Q2 2026.
  • Jupiter Asset Management bought 125,834 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $85.7M.
  • Regeneron Pharmaceuticals made up 0.39% of Jupiter Asset Management's portfolio in Q2 2026, its #72 holding.
  • Jupiter Asset Management first reported a position in Regeneron Pharmaceuticals in Q3 2020 and has held it in 10 quarters since.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Jupiter Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.